Neoplasms

All Conditions

Digestive System Diseases

Carcinoma

Carcinoma, Hepatocellular

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

All Drugs and Chemicals

Hematinics

Nootropic Agents

Gastrointestinal Agents

Lipid Regulating Agents

Vitamins

Fluorodeoxyglucose F18

Liver Extracts

Choline

Hypolipidemic Agents

Antimetabolites

Prospective inclusion of patients who are candidates for a transplant for CHC at the University Hospital of Lille and Rouen whose transplant project has been validated with a AFP score ≤ 2.

The systematic performance of a PET-CT with FDG and a PET-CT with Choline in all patients. At the end of the entire assessment, the patients will be (or not) registered on the transplant list and, for the patients registered on the list, a follow-up will be carried out at the level of a specialized transplant consultation every 3 months at during which the alphafoetoprotein dosage and abdominal imaging will be updated, until liver transplantation.

Performing an FDG TDM PET and a Choline TDM PET at two different times

PET TDM FDG-Choline

Guillaume Lassailly, MD

HCC is the most common malignant liver tumor for which liver transplantation is one of the pivotal curative treatments. The best possible selection of patients who are candidates for transplantation is essential in the current context of a shortage of transplants. Performing a PET CT scan is not currently recommended in the pre-liver transplant workup for HCC. However, PET CT using in a complementary manner the FDG and Choline tracers appears promising in the management of HCC in view of its wide use in oncology and its major diagnostic and prognostic contribution compared to conventional imaging. In order to address this issue, a prospective cohort study including patients from the University Hospital of Rouen and Lille with hepatocellular carcinoma meeting the criteria for indication of liver transplantation validated in SPC will be set up, the main objective of which will be to assess the decision-making contribution of PET TDM FDG and Choline in addition to conventional imaging in the pre-transplant assessment.

PET TDM FDG-Choline as a Decision-making Tool for Routine Care on the Liver Transplant List for HCC

Evaluation of PET TDM FDG-Choline as a Decision-making Tool for Routine Care on Inclusion on the Liver Transplant List for Hepatocellular Carcinoma

Composite endpoint corresponding to the rate of patients reclassified for lymph node fixation (N +) and / or extrahepatic extension (M +) after PET TDM FDG-Choline with a negative standard assessment (thoracic CT, abdominal imaging by CT or MRI) or patient not included on the list due to locally advanced disease not compatible with the graft (AFP score ≥ 3 or infiltrating HCC) not identified by the standard assessment.

Presence/absence of a double fixation TEP FDG and TEP Choline B. Presence of a single TEP FDG or Choline binding C. No FDG-Choline binding.

University Hospital, Lille

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
PET TDM FDG-Choline as a Decision-making Tool for Routine Care on the Liver Transplant List for HCC	NCT04792801	Hepatocellular ... Liver Transplan...	PET TDM FDG-Cho...	18 Years -	University Hospital, Lille
PET TDM FDG-Choline as a Decision-making Tool for Routine Care on the Liver Transplant List for HCC	NCT04792801	Hepatocellular ... Liver Transplan...	PET TDM FDG-Cho...	18 Years -	University Hospital, Lille
PET TDM FDG-Choline as a Decision-making Tool for Routine Care on the Liver Transplant List for HCC	NCT04792801	Hepatocellular ... Liver Transplan...	PET TDM FDG-Cho...	18 Years -	University Hospital, Lille

Spots Global Cancer Trial Database for pet ct, fluorodeoxyglucose